Half-year report · HY
5988.TEDINET S100X3UK
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥30.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥63.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥845m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥787m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥536m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥435m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥437m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥99.3bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥105.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥124.1bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.3bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥13.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥65.0bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥91.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥111.7bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥25.3bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥34.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.4bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥30.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥24.8bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥8.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥3.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥16.49 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.67 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 64.2% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| Automobile Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥27.5bn |
| Automobile Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥27.5bn |
| Automobile Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Medicalreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| Medicalreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| Medicalreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥83m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥30.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥30.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥1.4bn |
| Automobile Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥29.3bn |
| Automobile Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥29.3bn |
| Automobile Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Medicalreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Medicalreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Medicalreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥226m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥31.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥31.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 504
| Item | Context | Value | Unit |
|---|---|---|---|
| Salaries and allowances sga | Prior1InterimDuration | 1873000000 | JPY |
| Salaries and allowances sga | InterimDuration | 1810000000 | JPY |
| Packing and delivery expenses sga | Prior1InterimDuration | 1037000000 | JPY |
| Packing and delivery expenses sga | InterimDuration | 988000000 | JPY |
| Depreciation sga | Prior1InterimDuration | 351000000 | JPY |
| Depreciation sga | InterimDuration | 431000000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 281000000 | JPY |
| Provision for bonuses sga | InterimDuration | 235000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 18000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 22000000 | JPY |
| Provision for share based remuneration for directors and other officers sga | Prior1InterimDuration | 28000000 | JPY |
| Provision for share based remuneration for directors and other officers sga | InterimDuration | 14000000 | JPY |
| Provision for share based remuneration sga | Prior1InterimDuration | 4000000 | JPY |
| Provision for share based remuneration sga | InterimDuration | 2000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E01438-000AutomobileRelatedReportableSegmentsMember | 29313000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E01438-000MedicalReportableSegmentsMember | 2633000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 31946000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E01438-000AutomobileRelatedReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E01438-000MedicalReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E01438-000AutomobileRelatedReportableSegmentsMember | 29313000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E01438-000MedicalReportableSegmentsMember | 2633000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 31946000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E01438-000AutomobileRelatedReportableSegmentsMember | 1617000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E01438-000MedicalReportableSegmentsMember | 226000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1844000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E01438-000AutomobileRelatedReportableSegmentsMember | 27530000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E01438-000MedicalReportableSegmentsMember | 2529000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 30060000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E01438-000AutomobileRelatedReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E01438-000MedicalReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E01438-000AutomobileRelatedReportableSegmentsMember | 27530000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E01438-000MedicalReportableSegmentsMember | 2529000000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 30060000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E01438-000AutomobileRelatedReportableSegmentsMember | 1294000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E01438-000MedicalReportableSegmentsMember | 83000000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1378000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-13 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第110期中（自 2025年４月１日 至 2025年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社パイオラックス | |
| Company name in english cover page | FilingDateInstant | PIOLAX,INC. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 山田 聡 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)横浜市保土ケ谷区岩井町51番地 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | ０４５（５７７）３８８０ | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)経営管理部長 福田 俊宏 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)横浜市保土ケ谷区岩井町51番地 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |